


GAVI'S ROLE IN A FUTURE COVID-19 VACCINE PROGRAMME

BOARD MEETING

Derrick Sim, Richard Mihigo

7-8 December 2022, Geneva, Switzerland



Why should Gavi support a future COVID-19 programme?

Impact to date...




Recent modelling estimates that **COVAX**-supported COVID-19 doses have averted over **1.7 million** deaths across AMC participants



AMCs look to COVAX to supply a **large proportion** of their COVID-19 doses – with **LICs relying on COVAX** for ~75% of their supply – providing continued access critical for global fight against COVID-19

Current epidemiology...



Many regions are experiencing a **surge as several variants continue to co-circulate**. Some countries are experiencing their highest ever incidence, **although vaccination has helped reduce severe disease and death**.

Looking ahead...



Initial **impact projections** show **deaths averted per fully vaccinated person**, especially for higher-risk populations, are in the **same range as those of other Gavi-supported vaccine programmes**



A COVID-19 programme can **support and strengthen platforms for life-course vaccination** and contribute to learnings on integration of immunisation into primary health care in view of Gavi 6.0



Strategic Objective

Shift from an **emergency response** focused on global health security to **protection of the most vulnerable**, while retaining ability to quickly mobilise in a worst-case scenario

Planning in the face of unprecedented uncertainty

Continued uncertainty persists around:



Predictability of **surges and seasonality**



New variants that could be more severe and/or more transmissible



Continued demand for COVID-19 vaccines



Long term protection against severe disease and death



Evolution of products and implications on efficacy, durability and programmatic feasibility

Recognising the **need to start planning**, the Secretariat is proposing to move forward with a **phased approach** with humility, using the **best information available**, understanding that our **assumptions can change** with new information

Deep-dive into delivery: approach, costing and operationalisation

Approach

- Continue to **reach high-risk groups with booster doses**
- Begin to **strengthen health systems' capacities** to deliver COVID-19 vaccination sustainably through more regular PHC services
- Continue to learn what it takes for countries to **routinely reach adult target populations**

Cost

2024-2025 delivery envelope

~US\$ 220 million

+

2024-2025 TA

~US\$ 47 million

Operationalisation

- Delivery funding **integrated into HSS envelope** and **Partners' Engagement Framework (PEF)**; no separate CDS
- Streamlines Gavi support by **reducing complexity and transaction costs**
- Captures **synergies** between infant, adolescent and adult immunisation
- Leverage COVID-19 investments for **RI**

Proposed approach for Phase 1 of the COVID-19 Vaccine Programme in 2024-2025

Overall Approach

Population cohort

- **Continued focus on the higher priority user groups** according to SAGE recommendation (older, immunocompromised, pregnant persons, adults with comorbidities, and healthcare workers – approximately 20% of total population)

Country scope

- Continued but **differentiated support to the AMC91¹** (Gavi54 and AMC37)

Co-financing and extent of support

- **Gavi54:** Eligible for **full vaccine procurement support** without co-financing obligations; 70% of estimated delivery costs
- **AMC37:** Provide support for **50% of COVID-19 procurement costs for one year** in line with the MICs Approach; not eligible for delivery support

Demand Considerations

- Plan based on realistic demand assumptions
- Booster coverage projected at 35-55% of higher priority user groups (Annex C)
- Current envelope enables 35% coverage of target cohort
- Demand will be updated regularly to guide procurement volumes
 - Alliance tender approach allows lower volumes to be procured, if demand falls
 - Gavi can secure additional doses, incl. through dose donations, if demand increases

The above approach adds up to a total envelope of **~US\$ 1.8 billion** for Gavi in the 2024-2025 period, with US\$ 1.5 billion for Gavi54

Would be sufficient to finance

100-120 million doses per year over phase one

1. Separate proposal for India to be considered as done with previous Gavi Board tailored strategy for COVAX in 2020

Recommendation (1/2)

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

- a) **Approve**, in principle, a new programme for COVID-19 vaccination, phase one of which will be implemented in 2024-2025, contingent on:
 - a. Continuation of the WHO base-case scenario for the pandemic evolution requiring continued focus on the higher priority user groups as per SAGE recommendation;
 - b. Sufficient funding as confirmed by the Board by June 2023
 - c. Updated country demand estimates informing volume requirements; and
 - d. Further information from country experience and use of COVID-19 Delivery Support (CDS) to date.
- b) **Approve**, in principle, the following country scope and extent of support for phase one of the new COVID-19 programme:
 - a. Country scope: AMC91 (Gavi54 and AMC37)
 - b. Extent of support:
 - i. Gavi54: Eligible for full vaccine procurement support without co-financing obligations and delivery support (consisting of the provision of 70% of estimated total delivery costs for the vaccines).
 - ii. AMC37: Eligible for vaccine catalytic financing in line with the MICs Approach for vaccine procurement and not eligible for delivery support.

Recommendation (2/2)

- c) **Acknowledge** that planning for phase one, including engagement with countries, for a COVID-19 programme would commence before funding commitments come for approval by June 2023 to ensure the feasibility of a timely launch by 2024.

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Note** that the Secretariat will update programme assumptions and the approach for phase one of the COVID-19 programme, incorporating the latest demand estimates and the latest information on delivery, as informed by the implementation of CDS3;
- b) **Note** that the Secretariat will return to the Board by June 2023 for approval of the final programme design and the financial envelope for 2024-2025;
- c) **Note** that the Secretariat will update the Board at each meeting and will return to the Board formally, through the PPC, if future SAGE guidance evolves such that this programme is no longer aligned with technical guidance and/or assumptions outlined in Annex C to Doc 10 vary significantly as to affect the implementation feasibility of the programme; and
- d) **Note** that the Secretariat will return to the Board as part of the Gavi 6.0 strategy development with proposed updates to the COVID-19 vaccination programme to account for changes in disease epidemiology as well as consideration of Gavi 6.0 priorities.



Thank you